Biocryst Pharmaceuticals (BCRX) Total Liabilities (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Total Liabilities came in at $1.0 billion in Q1 2026, up 9.33% YoY from $932.0 million in Q1 2025, and up 60.88% on a QoQ basis from $633.3 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Total Liabilities (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Total Liabilities data on file, last reported at $1.0 billion in Q1 2026.
- Quarterly Total Liabilities rose 9.33% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 9.33% YoY) and the FY2025 annual result came in at $633.3 million, down 34.46% from the prior year.
- Total Liabilities grew to $1.0 billion in Q1 2026, from $633.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $1.0 billion in Q1 2026 to a low of $467.9 million in Q1 2024.
- A 5-year average of $696.8 million and a median of $558.6 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 110.19% — and 2025, when it plunged 34.46%.
- Tracing BCRX's Total Liabilities over 5 years: stood at $550.0 million in 2022, then soared by 76.82% to $972.5 million in 2023, then retreated by 0.63% to $966.4 million in 2024, then sank by 34.46% to $633.3 million in 2025, then soared by 60.88% to $1.0 billion in 2026.
- The last three Total Liabilities figures came in at $1.0 billion (Q1 2026), $633.3 million (Q4 2025), and $834.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.12 Bn |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 1.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Bn |
| Mar 31, 2026 | 1.02 Bn |
| Dec 31, 2025 | 633.31 Mn |
| Sep 30, 2025 | 834.31 Mn |
| Jun 30, 2025 | 878.78 Mn |
| Mar 31, 2025 | 931.97 Mn |
| Dec 31, 2024 | 966.35 Mn |
| Sep 30, 2024 | 959.82 Mn |
| Jun 30, 2024 | 472.42 Mn |
| Mar 31, 2024 | 467.89 Mn |
| Dec 31, 2023 | 972.49 Mn |
| Sep 30, 2023 | 522.92 Mn |
| Jun 30, 2023 | 529.89 Mn |
| Mar 31, 2023 | 509.74 Mn |
| Dec 31, 2022 | 550.00 Mn |
| Sep 30, 2022 | 558.59 Mn |
| Jun 30, 2022 | 510.54 Mn |
| Mar 31, 2022 | 527.72 Mn |
| Dec 31, 2021 | 588.15 Mn |
| Sep 30, 2021 | 265.76 Mn |